Santen Pharmaceutical Co (JP:4536) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Santen Pharmaceutical Co. has successfully repurchased 3,729,200 common shares totaling over 6.29 billion yen as part of its share buyback program implemented in November 2024. The buyback is a strategic move to enhance shareholder value, with a maximum target of 5 million shares and a budget of 10 billion yen set by the company.
For further insights into JP:4536 stock, check out TipRanks’ Stock Analysis page.